Advertisement CryoCath launches Arctic Front catheter in Hong Kong - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

CryoCath launches Arctic Front catheter in Hong Kong

CryoCath Technologies, a provider of cryotherapy products to treat cardiac arrhythmias, has introduced its Arctic Front catheter in Hong Kong.

CryoCath’s Arctic Front, which is used for the treatment of paroxysmal atrial fibrillation (PAF), is a unique cryoablation balloon catheter that allows physicians to safely and effectively isolate all four pulmonary veins in the treatment of PAF. Arctic Front will be exclusively distributed in Hong Kong by Pacific Medical.

Jan Keltjens, president and CEO of CryoCath, said: “We are extremely proud to see Arctic Front expand into new markets beyond Europe, first in Australia, and now in Hong Kong. With our rapidly growing body of clinical evidence, we are confident that our Arctic Front system will continue to broaden its user base.”